• Product NameSNS-032 (BMS-387032)
• Brief DescriptionInhibitors
• Purification99.00%
• Biological ActivitySNS-032 has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. Phase 1.
• Target NameCDK inhibitor; GSK-3 inhibitor
• CAS No. 345627-80-7
• Calculated MW 380.53
• Formulation C17H24N4O2S2
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CC(C)(C)C1=CN=C(CSC2=CN=C(NC(=O)C3CCNCC3)S2)O1 |t:4,6,10,12|
  Pathways:PI3K/Akt/mTOR signaling; Cell Cycle/Checkpoint; Stem Cells
  Receptor:CDK2/CyclinA; CDK2/CyclinE; CDK7/CyclinH; CDK9/CyclinT; GSK-3α
  Boling pt:
  Melting pt:
  Solubility:DMSO:76 mg/mL (199.72 mM)Ethanol:<1 mg/mL (<1 mM)Water:<1 mg/mL (<1 mM)
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Chen R, et al. Blood, 2009, 113(19): 4637-45.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting